{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-020891","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.787952+00:00","generated_at":"2026-05-17T00:24:22.366064+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance","bullets":["Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.","Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.","Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.","Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.","Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-020891","json":"https://secwatch.observer/filing/0001493152-25-020891.json","markdown":"https://secwatch.observer/filing/0001493152-25-020891.md","text":"https://secwatch.observer/filing/0001493152-25-020891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/0001493152-25-020891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:24:22.366064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}